• LY2603618: A Precision Chk1 Inhibitor for Cancer Research

  2026-06-09

  LY2603618 stands out as a highly selective Chk1 inhibitor, enabling researchers to dissect DNA damage responses and optimize cancer chemotherapy sensitization. This guide translates the latest redox-focused findings and practical workflows into actionable protocols for non-small cell lung cancer and beyond.

• Demethyleneberberine Induces Senescence in NSCLC via c-Myc/H

  2026-06-09

  This study demonstrates that Demethyleneberberine (DMB), a natural isoquinoline alkaloid, induces cell cycle arrest and senescence in non-small cell lung cancer (NSCLC) cells by downregulating the c-Myc/HIF-1α pathway. These findings provide mechanistic insight into DMB’s anti-tumor activity and offer a rationale for its use as a research tool in NSCLC and related disease models.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Applied Ins

  2026-06-08

  The JC-1 Mitochondrial Membrane Potential Assay Kit empowers precise, ratiometric detection of mitochondrial health, enabling high-content apoptosis and function analysis across diverse research models. Its robust dual-fluorescence workflow, paired with reliable controls, accelerates translational breakthroughs in cancer and immunology. Discover optimized protocols, troubleshooting strategies, and real-world applications that set this APExBIO kit apart.

• Torin2 and the Future of mTOR Inhibition in Translational On

  2026-06-08

  This thought-leadership article explores the mechanistic depth and translational opportunities offered by Torin2, a next-generation mTOR inhibitor, in light of emerging insights into apoptotic signaling and RNA Pol II biology. We integrate recent findings, protocol best practices, and competitive positioning to provide actionable guidance for cancer researchers seeking to unravel the complexities of the PI3K/Akt/mTOR pathway.

• ATRA Overcomes PARP Inhibitor Resistance in Platinum-Treated

  2026-06-07

  This study demonstrates that all-trans retinoic acid (ATRA) can sensitize epithelial ovarian cancer (EOC) cells to PARP inhibition following cisplatin-induced resistance. The findings provide a mechanistic basis for combining ATRA with PARP inhibitors such as Niraparib to improve outcomes in platinum-resistant EOC models.

• Artesunate: Mechanisms and Benchmarks for Cancer Research

  2026-06-06

  Artesunate is a high-purity artemisinin derivative with robust anti-cancer properties, including potent inhibition of small cell lung carcinoma in vitro. Its mechanisms involve both ferroptosis induction and caspase-11-mediated pyroptosis inhibition, supporting its use as a precision tool in oncology research.

• PD 0332991 (Palbociclib) HCl: Precision in Rb-Driven Tumor S

  2026-06-05

  Explore the advanced biology and translational promise of PD 0332991 (Palbociclib) HCl, a selective CDK4/6 inhibitor, with a focus on Rb pathway vulnerabilities and protocol optimization. This article offers unique insights for oncology research and assay design.

• Machine Learning for Predicting LNPs in mRNA Vaccine Design

  2026-06-05

  This study pioneers the use of machine learning to predict the efficacy of lipid nanoparticle (LNP) formulations for mRNA vaccines, highlighting the critical role of ionizable lipids like Dlin-MC3-DMA. The integration of computational modeling and experimental validation accelerates LNP optimization, offering a robust framework for advancing RNA delivery technologies.

• Norovirus Utilizes NINJ1 for Selective Viral Protein Secreti

  2026-06-04

  This study reveals how murine norovirus (MNoV) hijacks the host cell death effector NINJ1 to orchestrate the selective secretion of its NS1 protein, leveraging caspase-3–mediated cleavage and NINJ1 oligomerization. These findings provide a mechanistic bridge between programmed cell death, unconventional secretion pathways, and viral immune evasion strategies.

• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate

  2026-06-04

  This study introduces a robust, multi-step protocol for synthesizing deuterium-labeled degarelix acetate—a pivotal internal standard for clinical pharmacokinetics and androgen-related disease research. The methodology streamlines isotope incorporation and peptide assembly, enhancing the reproducibility and scalability of tracer studies in advanced metabolic and drug development workflows.

• Annular Sector Microneedle Enables Targeted Gene Delivery fo

  2026-06-03

  This study presents an engineered annular sector-shaped microneedle patch for localized co-delivery of nicotinamide and Nmnat1 gene-loaded lipid nanoparticles to the trabecular meshwork, reversing mitochondrial dysfunction in glaucoma. The approach demonstrates improved bioavailability, intraocular pressure control, and restoration of tissue function, highlighting a novel combinatorial platform for targeted ocular gene therapy.

• TG003: Potent Cdc2-like Kinase Inhibitor for Splicing Resear

  2026-06-03

  TG003 is a nanomolar-potency Cdc2-like kinase inhibitor used to dissect alternative splicing mechanisms and model platinum resistance in cancer. It acts selectively on Clk1 and Clk4, modulating splice site selection by inhibiting SR protein phosphorylation. TG003 supports translational workflows from mechanistic cancer studies to exon-skipping therapy development.

• A1 vs. AMD3100: Advancing CXCR4 Inhibition in Colorectal Can

  2026-06-02

  The reference study introduces A1, a novel fluorinated CXCR4 inhibitor, and demonstrates its superior anti-tumor efficacy over AMD3100 in colorectal cancer models. These findings highlight the evolving landscape of CXCR4-targeted therapies and suggest new avenues for cancer metastasis inhibition research.

• Verbascoside: Advanced PKC/NF-κB Inhibition in Neuroinflamma

  2026-06-02

  Explore how Verbascoside serves as a precise PKC/NF-κB inhibitor, uniquely bridging bone metabolism and neuroinflammation studies. Discover mechanistic insights, protocol guidance, and scientific context grounded in the latest research.

• Gastrin I (human): Reliable Solutions for GI Assay Challenge

  2026-06-01

  This article examines common experimental challenges in gastric acid secretion pathway research and demonstrates how 'Gastrin I (human)' (SKU B5358) from APExBIO addresses reproducibility, compatibility, and interpretability in advanced in vitro assays. Scenario-driven Q&A blocks guide biomedical researchers in leveraging this high-purity peptide for robust gastrointestinal physiology studies.

14592 records 1/973 page Next 12345 下5页 Last page